DB:LSI

Stock Analysis Report

CK Life Sciences Int'l. (Holdings)

Executive Summary

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research, development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America.


Snowflake Analysis

Acceptable track record and slightly overvalued.


Similar Companies

Share Price & News

How has CK Life Sciences Int'l. (Holdings)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LSI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.2%

LSI

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

168.9%

LSI

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: LSI exceeded the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: LSI exceeded the German Market which returned 8.3% over the past year.


Shareholder returns

LSIIndustryMarket
7 Day5.2%-4.1%-5.7%
30 Day24.1%-8.2%-5.7%
90 Day41.5%-2.0%-3.6%
1 Year176.0%168.9%4.0%3.7%9.3%6.1%
3 Year55.0%45.8%38.2%36.7%8.9%-0.7%
5 Year54.7%42.4%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is CK Life Sciences Int'l. (Holdings)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CK Life Sciences Int'l. (Holdings) undervalued compared to its fair value and its price relative to the market?

36.14x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: LSI (€0.12) is trading above our estimate of fair value (€0.01)

Significantly Below Fair Value: LSI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: LSI is good value based on its PE Ratio (36.1x) compared to the Biotechs industry average (38x).

PE vs Market: LSI is poor value based on its PE Ratio (36.1x) compared to the German market (20.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LSI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LSI is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is CK Life Sciences Int'l. (Holdings) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CK Life Sciences Int'l. (Holdings) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has CK Life Sciences Int'l. (Holdings) performed over the past 5 years?

0.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LSI has a large one-off gain of HK$160.0M impacting its June 30 2019 financial results.

Growing Profit Margin: LSI's current net profit margins (5%) are lower than last year (5.3%).


Past Earnings Growth Analysis

Earnings Trend: LSI's earnings have grown by 0.3% per year over the past 5 years.

Accelerating Growth: LSI's earnings growth over the past year (1.6%) exceeds its 5-year average (0.3% per year).

Earnings vs Industry: LSI earnings growth over the past year (1.6%) exceeded the Biotechs industry -4.7%.


Return on Equity

High ROE: LSI's Return on Equity (6.9%) is considered low.


Next Steps

Financial Health

How is CK Life Sciences Int'l. (Holdings)'s financial position?


Financial Position Analysis

Short Term Liabilities: LSI's short term assets (HK$3.1B) exceed its short term liabilities (HK$1.3B).

Long Term Liabilities: LSI's short term assets (HK$3.1B) do not cover its long term liabilities (HK$4.8B).


Debt to Equity History and Analysis

Debt Level: LSI's debt to equity ratio (111.2%) is considered high.

Reducing Debt: LSI's debt to equity ratio has increased from 72.5% to 111.2% over the past 5 years.

Debt Coverage: LSI's debt is not well covered by operating cash flow (6.1%).

Interest Coverage: LSI's interest payments on its debt are not well covered by EBIT (2.9x coverage).


Balance Sheet

Inventory Level: LSI has a high level of physical assets or inventory.

Debt Coverage by Assets: LSI's debt is not covered by short term assets (assets are 0.6x debt).


Next Steps

Dividend

What is CK Life Sciences Int'l. (Holdings)'s current dividend yield, its reliability and sustainability?

1.01%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: LSI's dividend (1.01%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.38%).

High Dividend: LSI's dividend (1.01%) is low compared to the top 25% of dividend payers in the German market (3.73%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, LSI has been paying a dividend for less than 10 years.

Growing Dividend: LSI's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (36.5%), LSI's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Hing Lam Kam (73yo)

HK$3,825,000

Compensation

Mr. Kam Hing Lam, B.ScE, MBA has been Deputy Managing Director and Executive Director of CK Asset Holdings Limited (formerly Cheung Kong Property Holdings Limited) since February 26, 2015. Mr. Kam has been ...


Leadership Team

NamePositionTenureCompensationOwnership
Tzar Kuoi Li
Executive Chairman 17.8yrsHK$75.00k0.023% HK$263.3k
Hing Lam Kam
President0yrsHK$3.83m0.065% HK$728.4k
Ying Choi Yu
VP, COO0yrsHK$13.00m0.023% HK$263.3k
Tak Chuen Ip
Senior VP0yrsHK$2.08m0.023% HK$263.3k
Kean Meng Toh
Chief Scientific Officer & Executive Director1.3yrsHK$3.80mno data
Kee Chu
Vice President1.3yrsHK$3.42mno data
Yiu Leung Mo
Vice President of Finance0yrsno datano data
Mai Kuen Lee
Chief Manager of Personnel & Administration0yrsno datano data
King Sang Hon
Legal Counsel17.7yrsno datano data
Wai Che W. Tong Barnes
Chief Corporate Affairs Officer0yrsno datano data

1.3yrs

Average Tenure

61yo

Average Age

Experienced Management: LSI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Tzar Kuoi Li
Executive Chairman 17.8yrsHK$75.00k0.023% HK$263.3k
Hing Lam Kam
President0yrsHK$3.83m0.065% HK$728.4k
Ying Choi Yu
VP, COO0yrsHK$13.00m0.023% HK$263.3k
Tak Chuen Ip
Senior VP0yrsHK$2.08m0.023% HK$263.3k
Kean Meng Toh
Chief Scientific Officer & Executive Director1.3yrsHK$3.80mno data
Eva Kwok
Independent Non-Executive Director17.7yrsHK$180.00k0.0021% HK$23.4k
Keith Frankel
Co-Chairman of Vitaquest International LLC0yrsno datano data
Peter Peace Tulloch
Non-Executive Director17.8yrsHK$75.00k0.011% HK$122.8k
Hing Lam
Chairman of Australian Agribusiness Pty Ltd0yrsHK$2.55mno data
Kai Cheong Kwan
Independent Non-executive Director1.8yrsHK$155.00kno data

17.7yrs

Average Tenure

65yo

Average Age

Experienced Board: LSI's board of directors are seasoned and experienced ( 17.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

CK Life Sciences Int'l., (Holdings) Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CK Life Sciences Int'l., (Holdings) Inc.
  • Ticker: LSI
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$9.515b
  • Listing Market Cap: HK$1.125b
  • Shares outstanding: 9.61b
  • Website: https://www.ck-lifesciences.com

Number of Employees


Location

  • CK Life Sciences Int'l., (Holdings) Inc.
  • 2 Dai Fu Street
  • Tai Po Industrial Estate
  • Tai Po
  • New Territories
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CKLS.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2002
775SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJul 2002
LSIDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2002
LSIBRSE (Berne Stock Exchange)YesOrdinary SharesCHCHFJul 2002

Biography

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research, development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines. The company is also involved in the contract manufacturing of complementary healthcare medicines, vitamins, nutritional supplements, and cosmetics; licensing registration activities and the importation of finished agricultural goods; holding land and building; financing and trustee activities; investment in financial instruments, as well as vineyards and wineries; trading of biotechnology products and nutritional supplements; and the manufacturing, wholesale, retailing, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as turf fertilizers, chemicals, and professional pest products; produces, refines, and distributes salt products; and provides services in the research and development of bio-technology and life sciences technology products. Further, it engages in the discovery, development, manufacture, and commercialization of drug products to treat pain and melanoma; and supply of raw materials for nutritional health, pharmaceutical, cosmetics, personal care, and food segments. Additionally, the company offers packing and asset management services. CK Life Sciences Int'l., (Holdings) Inc. is headquartered in Tai Po, Hong Kong. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 21:13
End of Day Share Price2020/02/24 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.